Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > August 30, 2022
Daily News
August 30, 2022
- Japan Approves AstraZeneca’s COVID-19 Cocktail Therapy Evusheld
August 30, 2022
- Pfizer’s COVID Booster Approved for Children Aged 5-11 in Japan
August 30, 2022
- LDP Group Eyes Proposal on Generic Distribution, Pricing; Expert Wants Penalty on Healthcare Providers Getting Undue Discounts
August 30, 2022
- Stelues Shipments to Get Back to Normal in September: Pfizer Japan
August 30, 2022
- AZ’s Asthma Drug Tezepelumab Clears MHLW Panel Review; BMS’ Psoriasis Med, MSD/Sanofi Jabs Too
August 30, 2022
- AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
August 30, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…